Catherine Boegner
Overview
Explore the profile of Catherine Boegner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bonnet J, Tournayre S, Anitcheou J, Faivre M, Boegner C, Jalek A, et al.
Obesity (Silver Spring)
. 2023 Nov;
32(1):50-58.
PMID: 37927153
Objective: This retrospective cohort study aimed to assess the effectiveness of semaglutide 2.4 mg in patients with severe obesity (BMI ≥ 40 kg/m ) who had previously undergone bariatric surgery...
2.
Lohan L, Clement F, Duflos C, Villiet M, Castet-Nicolas A, Boegner C, et al.
J Patient Saf
. 2020 Aug;
17(8):e1034-e1039.
PMID: 32773647
Objectives: This study aimed to investigate a potential daily-life concern for patients with diabetes hypoglycemia while driving by (1) estimating their incidence in insulin-treated drivers, (2) determining factors associated with...
3.
Pawelzik S, Avignon A, Idborg H, Boegner C, Stanke-Labesque F, Jakobsson P, et al.
Prostaglandins Other Lipid Mediat
. 2019 Aug;
145:106361.
PMID: 31419481
Obesity is associated with low-grade chronic inflammation, which contributes to the development of the metabolic syndrome and its associated complications, such as insulin resistance and type-2 diabetes. Limited data from...
4.
Breuker C, Clement F, Mura T, Macioce V, Castet-Nicolas A, Audurier Y, et al.
Int J Cardiol
. 2018 Jul;
268:195-199.
PMID: 30041785
Background: Cardiovascular diseases are the first cause of mortality in patients with diabetes, and LDL-cholesterol is a well-established cardiovascular risk factor. This study aimed to assess rate of LDL-cholesterol target...
5.
Boursier G, Sultan A, Molinari N, Maimoun L, Boegner C, Picandet M, et al.
Clin Biochem
. 2017 Dec;
53:8-12.
PMID: 29225096
Objective: Assessment of insulin resistance (IR) is essential in non-diabetic patients with obesity. Thus study aims to identify the best determinants of IR and to propose an original approach for...
6.
Breuker C, Macioce V, Mura T, Castet-Nicolas A, Audurier Y, Boegner C, et al.
J Patient Saf
. 2017 Sep;
17(7):e645-e652.
PMID: 28877049
Objective: First, the aim of the study was to assess the prevalence, characteristics, and severity of unintended medication discrepancies (UMDs) and medication errors (MEs) at admission and discharge of hospitalization....
7.
Al Masri M, Romain A, Boegner C, Maimoun L, Mariano-Goulart D, Attalin V, et al.
Appl Physiol Nutr Metab
. 2017 Feb;
42(4):438-442.
PMID: 28177726
Low plasma 25-hydroxy-vitamin D (25OHD) and high levels of parathyroid hormone (PTH) are associated with obesity and could play a role in the occurrence of complications such as insulin resistance....
8.
Breuker C, Abraham O, di Trapanie L, Mura T, Macioce V, Boegner C, et al.
Eur J Intern Med
. 2016 Dec;
38:38-45.
PMID: 28007439
Background: Medication errors (ME) are major public health issues in hospitals because of their consequences on patients' morbi-mortality. This study aims to evaluate the prevalence of ME at admission and...
9.
Boursier G, Avignon A, Kuster N, Boegner C, Leprieur E, Picandet M, et al.
Clin Lab
. 2016 May;
62(3):435-41.
PMID: 27156334
Background: Circulating procalcitonin (PCT) is an inflammatory marker produced by several cell types including adipose tissue following cytokine stimulation. A low-grade inflammation is well recognized in obese patients with insulin...
10.
Avignon A, Fesler P, Daien C, Costa D, Picot M, Roubille F, et al.
Presse Med
. 2015 Oct;
44 Suppl 1:S47-54.
PMID: 26476755
No abstract available.